Login to Your Account



Astellas Makes Hostile Bid for OSI; Will Roche Take the Bait?

By Jennifer Boggs


Tuesday, March 2, 2010
After a verbal offer to buy out OSI Pharmaceuticals Inc. for $52 per share - about $3.5 billion - failed to entice the company's board last month, Astellas Pharma Inc. is taking its bid straight to shareholders but may have to up its price to get the deal done. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription